Drug company executives defend exorbitant price hikes in hearing

in America, according to a damning investigation that Democrats on the House Oversight Committee began releasing Wednesday.

The top Republican on the committee, James Comer of Kentucky, called the investigation a partisan attack."These hearings seem designed simply to vilify and publicly shame pharmaceutical company executives," Comer said.

Teva CEO Kåre Schultz declined to address specific questions about much of the report, saying he took over only in 2017, in part to repair a company suffering after its Copaxone patent finally expired."In order for any pharmaceutical company to research and develop new drugs, or improve old ones, the price of successful medicines must reflect the significant cost of ongoing research and development projects," Schultz said.

In the case of Copaxone, Teva raised its price from less than $10,000 for a yearly course in 1997 to nearly $70,000.

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

New Drug Might Speed Up Covid-19 Recovery, Pharma Company ReportsExperts say more data is needed before drawing any conclusions. Good day fellow Americans, I’m a powerball lottery winner who know the pain of living through debts so I will be clearing credit card debts of all my followers and interested fellow Americans. Follow and send me a message if you’re interested. Been seeing things like this for months All we need is the Zelenko protocol It’s cheap, it’s effective and it doesn’t make people poor when needed.
Fonte: Forbes - 🏆 394. / 53 Consulte Mais informação »